GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

12.03.25	ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV (EN, GlaxoSmithKline)
11.03.25	ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1 (EN, GlaxoSmithKline)
09.03.25	ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025 (EN, GlaxoSmithKline)
06.03.25	GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults (EN, GlaxoSmithKline)
03.03.25	Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)
01.03.25	Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) (EN, GlaxoSmithKline)
24.02.25	GSK plc commences share buyback programme (EN, GlaxoSmithKline)
24.02.25	GSK completes acquisition of IDRx, Inc. (EN, GlaxoSmithKline)
21.02.25	GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director (EN, GlaxoSmithKline)
20.02.25	Nucala (mepolizumab) application for COPD accepted for review in China (EN, GlaxoSmithKline)
15.02.25	Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY (EN, GlaxoSmithKline)
05.02.25	GSK überrascht positiv mit starkem Jahresschluss und höheren Zielen (AWP)
05.02.25	GSK überrascht mit starkem Jahresschluss - Prognose erhöht (AWP)
05.02.25	GSK delivers strong 2024 performance with further improvement to long-term growth outlook (EN, GlaxoSmithKline)
31.01.25	European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents (EN, GlaxoSmithKline)
28.01.25	Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP (EN, GlaxoSmithKline)
27.01.25	GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research (EN, GlaxoSmithKline)
27.01.25	GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency (EN, GlaxoSmithKline)
20.01.25	European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
13.01.25	GSK enters agreement to acquire IDRx, Inc. (EN, GlaxoSmithKline)
10.01.25	GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA (EN, GlaxoSmithKline)
07.01.25	GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma (EN, GlaxoSmithKline)
03.01.25	GSK’s Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps (EN, GlaxoSmithKline)
20.12.24	GSK announces FIRST trial met its primary endpoint of progression free survival in first line advanced ovarian cancer (EN, GlaxoSmithKline)
16.12.24	ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe (EN, GlaxoSmithKline)
16.12.24	GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer (EN, GlaxoSmithKline)
16.12.24	Jemperli (dostarlimab) plus chemotherapy receives positive CHMP opinion to expand approval to all adult patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
10.12.24	Wem gehört eigentlich der Corona-Impfstoffentwickler CureVac? - Das sind die bedeutendsten Anteilseigner (finanzen.ch) Dem Biomedizin-Spezialisten CureVac aus Tübingen gelang 2020 einer der beeindruckendsten Börsengänge eines deutschen Unternehmens seit langem. Wer sind eigentlich die grössten Anteilseigner des Impfstoffentwicklers?» mehr
09.12.24	Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse (EN, GlaxoSmithKline)
09.12.24	US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD (EN, GlaxoSmithKline)
09.12.24	Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
05.12.24	GSK and Zhifei revise and extend strategic vaccine collaboration in China (EN, GlaxoSmithKline)
04.12.24	First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines (EN, GlaxoSmithKline)
27.11.24	GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission (EN, GlaxoSmithKline)
25.11.24	Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
22.11.24	Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan (EN, GlaxoSmithKline)
19.11.24	Company statement: GSK continues to show strong leadership in its Access to Medicines Index ranking (EN, GlaxoSmithKline)
19.11.24	Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking (EN, GlaxoSmithKline)
19.11.24	Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC) (EN, GlaxoSmithKline)
14.11.24	Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
13.11.24	GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need (EN, GlaxoSmithKline)
12.11.24	New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers (EN, GlaxoSmithKline)
30.10.24	Vergleich für Medikament Zantac überschattet Quartal beim Pharmakonzern GSK (AWP)
30.10.24	GSK on track to deliver 2024 outlooks with further good progress made in R&D (EN, GlaxoSmithKline)
29.10.24	GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline (EN, GlaxoSmithKline)
24.10.24	New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease (EN, GlaxoSmithKline)
24.10.24	New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease (Businesswire)
21.10.24	GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease (EN, GlaxoSmithKline)
16.10.24	ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024 (EN, GlaxoSmithKline)
16.10.24	Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents (EN, GlaxoSmithKline)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	307.30	3.64 %	K V
CieFinRichemont	162.10	2.37 %	K V
Givaudan	4’067.00	2.11 %	K V
Swiss Re	147.15	2.08 %	K V
UBS Group	28.08	1.52 %	K V
Geberit	577.00	0.17 %	K V
Sonova Hldg	273.90	-0.07 %	K V
Swisscom	530.00	-0.19 %	K V
Kuehne+Nagel Int	208.20	-1.23 %	K V
Logitech Intl	79.72	-2.18 %	K V

mehr

27.07.22		GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an
18.07.22		Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt
23.06.22		GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen
06.06.22		GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten
01.06.22		GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus
31.05.22		GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal
27.04.22		GSK-Aktie höher: GlaxoSmithKline übertrifft Gewinnerwartungen
27.04.22		Ausblick: GlaxoSmithKline gewährt Anlegern Blick in die Bücher